Jaguar Health will present crofelemer development updates on June 24 at the Life Sciences Virtual Investor Forum, highlighting its progress under CEO Lisa Conte. The company also plans two crofelemer presentations in pediatric microvillus inclusion disease and short bowel syndrome at the ESPGHAN meeting June 24–27.
Jaguar Health will host a live virtual presentation on June 24 at 1:00 PM Eastern at the Life Sciences Virtual Investor Forum, where CEO Lisa Conte will discuss milestones and timelines for crofelemer’s development in rare intestinal failure diseases. A replay will be available after the conference.
Jaguar Health plans two scientific presentations on crofelemer powder in pediatric patients with microvillus inclusion disease and short bowel syndrome–associated intestinal failure at the ESPGHAN Annual Meeting June 24–27, underscoring progress in orphan GI disorder research.
Jaguar Health develops plant-derived prescription therapies for complex gastrointestinal conditions through its family of companies, including Napo Pharmaceuticals and Napo Therapeutics, focused on commercialization of crofelemer for rare and orphan intestinal diseases.
